Literature DB >> 10536914

APOE and risk of cognitive impairment in multiple sclerosis.

R L Oliveri1, R Cittadella, G Sibilia, I Manna, P Valentino, A Gambardella, U Aguglia, M Zappia, N Romeo, V Andreoli, F Bono, M Caracciolo, A Quattrone.   

Abstract

OBJECTIVES: The APOE gene polymorphism and the -491 A/T polymorphism in its regulatory region have been associated with an increased risk for developing Alzheimer's disease. We examined these polymorphisms in multiple sclerosis (MS) patients, to determine if a genetic predisposition may explain the risk for developing cognitive decline in MS.
MATERIAL AND METHODS: Eighty-nine relapsing-remitting and secondary progressive MS patients underwent to a full neuropsychological battery as well as to determination of APOE and -491 A/T polymorphisms. Genetic analysis was also performed in 107 population controls.
RESULTS: The APOE polymorphism was not associated with the risk of cognitive impairment in MS patients. The AA genotype of the -491 A/T polymorphism in the APOE regulatory region was more frequent in cognitively impaired than in cognitively preserved MS subjects.
CONCLUSION: The AA homozygous state of the -491 A/T polymorphism of the APOE regulatory region is associated with cognitive impairment in patients with MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536914     DOI: 10.1111/j.1600-0404.1999.tb00398.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

1.  APOE epsilon4 and the cognitive genetics of multiple sclerosis.

Authors:  O Ghaffar; M Reis; N Pennell; P O'Connor; A Feinstein
Journal:  Neurology       Date:  2010-05-18       Impact factor: 9.910

Review 2.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

3.  Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis.

Authors:  Giovanni Savettieri; Demetrio Messina; Virginia Andreoli; Simona Bonavita; Carlo Caltagirone; Rita Cittadella; Deborah Farina; Maria Carolina Fazio; Paolo Girlanda; Francesco Le Pira; Maria Liguori; Alessandra Lugaresi; Ugo Nocentini; Arturo Reggio; Giuseppe Salemi; Gioacchino Tedeschi; Maria Trojano; Paola Valentino; Aldo Quattrone
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

4.  Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis.

Authors:  Silke Schmidt; Lisa F Barcellos; Karen DeSombre; Jacqueline B Rimmler; Robin R Lincoln; Patricia Bucher; Ann M Saunders; Eric Lai; Eden R Martin; Jeffery M Vance; Jorge R Oksenberg; Stephen L Hauser; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Am J Hum Genet       Date:  2002-02-11       Impact factor: 11.025

Review 5.  Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.

Authors:  Shumita Roy; Ralph H B Benedict; Allison S Drake; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

6.  ApoE alleles, depression and positive affect in multiple sclerosis.

Authors:  L J Julian; L Vella; D Frankel; S L Minden; J R Oksenberg; D C Mohr
Journal:  Mult Scler       Date:  2009-03       Impact factor: 6.312

7.  Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid.

Authors:  P D Mehta; B A Patrick; T Pirttila; P K Coyle; P S Aisen
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

8.  Interactions between the apolipoprotein E ε4 allele status and adverse childhood experiences on depressive symptoms in older adults.

Authors:  Subin Park; Yoon-Young Nam; Yoojin Sim; Jin Pyo Hong
Journal:  Eur J Psychotraumatol       Date:  2015-01-27

9.  ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study.

Authors:  Farshid Mashayekhi; Saeed Sadigh-Eteghad; Amirreza Naseri; Milad Asadi; Negin Abbasi Garravnd; Mahnaz Talebi
Journal:  Neurol Sci       Date:  2021-06-12       Impact factor: 3.307

Review 10.  Role of apolipoprotein E in neurodegenerative diseases.

Authors:  Vo Van Giau; Eva Bagyinszky; Seong Soo A An; Sang Yun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.